MA63879B1 - Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle - Google Patents
Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscleInfo
- Publication number
- MA63879B1 MA63879B1 MA63879A MA63879A MA63879B1 MA 63879 B1 MA63879 B1 MA 63879B1 MA 63879 A MA63879 A MA 63879A MA 63879 A MA63879 A MA 63879A MA 63879 B1 MA63879 B1 MA 63879B1
- Authority
- MA
- Morocco
- Prior art keywords
- paclitaxel
- treatment
- hyaluronic acid
- bladder cancer
- prodrug
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 4
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 4
- 229930012538 Paclitaxel Natural products 0.000 title abstract 3
- 229960001592 paclitaxel Drugs 0.000 title abstract 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 3
- 206010005003 Bladder cancer Diseases 0.000 title abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 2
- 230000008595 infiltration Effects 0.000 title abstract 2
- 238000001764 infiltration Methods 0.000 title abstract 2
- 210000003205 muscle Anatomy 0.000 title abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 230000003442 weekly effect Effects 0.000 abstract 2
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 abstract 1
- HSUDWURBWSUCOB-NUDIOSPNSA-N 7-(2′,3′′-dihydroxypropyl carbonoxy)paclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-NUDIOSPNSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une composition pharmaceutique, essentiellement constituée du promédicament du paclitaxel associé à des diluants/excipients pharmacologiquement acceptables, destinée à être utilisée dans le traitement du cancer de la vessie sans infiltration du muscle (tvnim) par instillations intravésicales, le schéma posologique consistant en une seule dose hebdomadaire de 600 mg dudit promédicament, ou en deux doses hebdomadaires pour une quantité totale de 1 200 mg, pendant 12 ou 6 semaines consécutives de traitement. Le promédicament du paclitaxel utilisé a été préparé selon un procédé de synthèse indirecte entre des molécules d'acide hyaluronique (ha) et de paclitaxel en introduisant un espaceur (acide 4-bromobutyrique) entre l'acide hyaluronique et l'agent chimiothérapeutique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| PCT/IB2019/059073 WO2020084525A1 (fr) | 2018-10-25 | 2019-10-23 | Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63879B1 true MA63879B1 (fr) | 2024-02-29 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63879A MA63879B1 (fr) | 2018-10-25 | 2019-10-23 | Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (fr) |
| EP (1) | EP3870233B1 (fr) |
| JP (1) | JP7518815B2 (fr) |
| KR (1) | KR102913965B1 (fr) |
| CN (2) | CN119792555A (fr) |
| CA (1) | CA3112188A1 (fr) |
| DK (1) | DK3870233T3 (fr) |
| EA (1) | EA202190614A1 (fr) |
| ES (1) | ES2971217T3 (fr) |
| FI (1) | FI3870233T3 (fr) |
| HR (1) | HRP20240188T1 (fr) |
| HU (1) | HUE066288T2 (fr) |
| IT (1) | IT201800009731A1 (fr) |
| LT (1) | LT3870233T (fr) |
| MA (1) | MA63879B1 (fr) |
| PL (1) | PL3870233T3 (fr) |
| PT (1) | PT3870233T (fr) |
| RS (1) | RS65193B1 (fr) |
| SI (1) | SI3870233T1 (fr) |
| SM (1) | SMT202400021T1 (fr) |
| WO (1) | WO2020084525A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) * | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2553099B1 (fr) | 1983-10-11 | 1989-09-08 | Fidia Spa | Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| ES2653679T3 (es) | 2011-11-09 | 2018-02-08 | Spinalcyte, Llc | Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/fr active Active
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 CA CA3112188A patent/CA3112188A1/fr active Pending
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/fr not_active Ceased
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2971217T3 (es) | 2024-06-04 |
| KR102913965B1 (ko) | 2026-01-16 |
| IT201800009731A1 (it) | 2020-04-25 |
| JP2022503771A (ja) | 2022-01-12 |
| EP3870233B1 (fr) | 2023-12-06 |
| FI3870233T3 (fi) | 2024-02-07 |
| LT3870233T (lt) | 2024-02-26 |
| SMT202400021T1 (it) | 2024-03-13 |
| PT3870233T (pt) | 2024-02-01 |
| DK3870233T3 (da) | 2024-02-05 |
| JP7518815B2 (ja) | 2024-07-18 |
| US20240123077A1 (en) | 2024-04-18 |
| CN119792555A (zh) | 2025-04-11 |
| EA202190614A1 (ru) | 2021-06-03 |
| PL3870233T3 (pl) | 2024-05-06 |
| CA3112188A1 (fr) | 2020-04-30 |
| US20210268119A1 (en) | 2021-09-02 |
| KR20210083249A (ko) | 2021-07-06 |
| US12465649B2 (en) | 2025-11-11 |
| EP3870233A1 (fr) | 2021-09-01 |
| HRP20240188T1 (hr) | 2024-05-10 |
| CN112805035A (zh) | 2021-05-14 |
| HUE066288T2 (hu) | 2024-07-28 |
| RS65193B1 (sr) | 2024-03-29 |
| WO2020084525A1 (fr) | 2020-04-30 |
| SI3870233T1 (sl) | 2024-03-29 |
| US20200397909A1 (en) | 2020-12-24 |
| US20210196833A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| IL300151A (en) | Combinations for cancer treatment | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| MA44205A (fr) | Comprimé orodispersible comprenant estetrol | |
| MA63879B1 (fr) | Conjugué de paclitaxel et d'acide hyaluronique dans le traitement du cancer de la vessie sans infiltration du muscle | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| KR20060017887A (ko) | 막 바이러스 증식을 저해하는 물질, 이의 제조 방법, 약학조성물 및 바이러스 감염의 저해 방법 | |
| MA29722B1 (fr) | Schema posologique pour le prasugrel | |
| Narang et al. | Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single‐centre pilot study. | |
| JP2018506533A5 (fr) | ||
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida | |
| RU2010107177A (ru) | Новые комбинации нерамексана для лечения нейродегенеративных расстройств | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| JP2022503771A5 (fr) | ||
| AR125470A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
| CN115243686A (zh) | 丁基苯酞及其衍生物的用途 | |
| JP2021521227A5 (fr) | ||
| PH12021552034A1 (en) | Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia | |
| EA202091320A1 (ru) | Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия | |
| RU2019140198A (ru) | Способ применения элементарной ртути для лечения онкологических заболеваний | |
| EA201991381A1 (ru) | Композиция для лечения остеоартрита |